Trial Profile
A Randomized, Phase IIb Study of CX-01 Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Dociparstat sodium (Primary) ; Cytarabine; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Cantex Pharmaceuticals; Chimerix
- 31 Jul 2019 Results published in the Chimerix Media Release.
- 31 Jul 2019 Status changed from active, no longer recruiting to completed, according to an Chimerix Media release.
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology